triazolam has been researched along with Autoimmune Diabetes in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "As triazolam was administered orally to Tsumura, Suzuki, obese, diabetes (TSOD) mice and streptozotocin (STZ) mice, clearance per body (CL/F) in TSOD mice did not differ compared with Tsumura, Suzuki, non-obesity (TSNO) mice." | 1.36 | Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice. ( Ikarashi, N; Kudo, T; Ochiai, W; Ohi, K; Sugiyama, K; Toda, T; Ushiki, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kudo, T | 1 |
| Toda, T | 1 |
| Ushiki, T | 1 |
| Ohi, K | 1 |
| Ikarashi, N | 1 |
| Ochiai, W | 1 |
| Sugiyama, K | 1 |
1 other study available for triazolam and Autoimmune Diabetes
| Article | Year |
|---|---|
Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice.
Topics: Animals; Blotting, Western; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diabetes Mellitu | 2010 |